The government has announced a robust plan to strengthen oversight of Pakistan’s pharmaceutical sector. A new collaboration between the Competition Commission of Pakistan (CCP) and the Drug Regulatory Authority (DRA) aims to regulate medicine prices, ensure consistent availability, and curb misleading promotions.
Under this joint framework, both agencies will share data, conduct policy research, and monitor market practices. The partnership also targets false advertising and unauthorized online marketing of medicines.
Salman Amin, a member of the CCP, emphasized that coordinated efforts are vital to stop deceptive online campaigns. Meanwhile, DRA CEO Dr. Ubaidullah confirmed that both institutions will work together to maintain uninterrupted access to essential medicines nationwide.
This move reflects the government’s commitment to protecting consumers while promoting transparency and accountability in the pharmaceutical industry.
#PharmaceuticalIndustry #MedicinePrices #DrugRegulation #HealthPakistan #ConsumerProtection #PharmaOversight #EssentialMedicines
